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HIV Clinical Management
The Clinical Significance of CD4
Counts in Asian and Caucasian
HIV-Infected Populations: Results
from TAHOD and AHOD
Amit C. Achhra, MBBS, MPH1, Jialun Zhou, PhD1, Jun Yong Choi, MD2,
Jennifer Hoy, MBBS, FRACP3, Fujie Zhang, MD4,
David J. Templeton, MB ChB, FAChSHM, PhD1,5, Tuti Merati, MD6,
Ian Woolley, MBBS, FRACP7, Kathy Petoumenos, PhD1, and
Janaki Amin, PhD1, for TAHOD and AHOD
Abstract
The significance of interethnic variation in CD4 counts between Asian and Caucasian populations is not known. Patients on
combination antiretroviral therapy from Treat Asia and Australian HIV Observational Databases (TAHOD, predominantly
Asian, n ¼ 3356; and AHOD, predominantly Caucasian, n ¼ 2312, respectively) were followed for 23 144 person-years for
AIDS/death and all-cause mortality endpoints. We calculated incidence-rates and used adjusted Cox regression to test for the
interaction between cohort (TAHOD/AHOD) and time-updated CD4 count category (lagged by 3 months) for each of the
endpoints. There were 382 AIDS/death events in TAHOD (rate: 4.06, 95%CI: 3.68-4.50) and 305 in AHOD (rate: 2.39,
95%CI: 2.13-2.67), per 100 person-years. At any given CD4 count category, the incidence-rates of endpoints were found to
be similar between TAHOD and AHOD (in the adjusted models, P > .05 for the interaction term between cohort type and latest
CD4 counts). At any given CD4 count, risk of AIDS or death was not found to vary by ethnicity, suggesting that the CD4 count
thresholds for predicting outcomes defined in Caucasian populations may be equally valid in Asian populations.
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Introduction
South-East and East Asian countries contribute over 10% of
global HIV burden, with over 4 million people living with HIV
infection.1 Traditionally, most clinical guidelines in HIV have
been developed on the basis of data collected from Caucasian
populations in Western countries and are extrapolated to
Asian HIV-infected populations.2-4 However, the clinical
significance of interethnic variation in immunological profile
between the 2 populations is not known.3
The CD4 T-cell lymphocyte count (CD4 count), one of the
most important clinical markers of HIV disease progression,2 is
known to have significant interethnic variation. For example,
several reference-range finding studies on healthy
HIV-uninfected individuals from the Asian region indicated
that Asians tend to have lower total lymphocyte and CD4
counts as compared to Caucasians.5-8 A recent study comparing
HIV-infected untreated patients from the Treat Asia HIV
Observational Database (TAHOD) (predominantly Asian) to
those from a French cohort showed that at any given CD4
percentage, Asians had lower CD4 counts, as compared to their
Caucasian counterparts.9 Furthermore, another study which
included patients from the TAHOD and the Australian HIV
Observational Database (AHOD) cohorts, suggested that
Asians have slightly lower CD4 count response after starting
combination antiretroviral therapy (cART), as compared to
Caucasians, even after accounting for baseline CD4 counts.10
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These findings give rise to the question of whether a given low
CD4 count implies a different magnitude of the risk of oppor-
tunistic infections or death in Asian and Caucasian
HIV-infected individuals.3 If prognostic significance of a given
level of CD4 count is found to be different between the 2 popu-
lations, it would imply that the CD4 thresholds defined on
Caucasianpopulationsmaynot be applicable toAsianpopulations.
In the present study, we model the relationship between
CD4 counts and AIDS or death and examine for possible het-
erogeneity in this relationship between the Asian and Cauca-
sian populations. We use data from the TAHOD and AHOD,
both being large prospective cohorts from the Asia-Pacific
region, founded on similar methodology and with well-validated
clinical endpoints.11,12
Methods
Study Population
The Treat Asia and Australian HIV Observational databases
(TAHOD and AHOD, respectively) are clinical cohort studies
of patientswithHIV infection inAsia andAustralia, respectively,
as a part of International Epidemiologic Databases to Evaluate
AIDS initiative. Both the cohorts have similar methodologies,
which have been published elsewhere.11,12 Briefly, prospective
data collection for TAHOD commenced in 2003, with retrospec-
tive data providedwhere available. InTAHOD, data are collected
from 17 clinical sites in Asian region. Written consent was not a
requirement of sites in TAHODunless required by the site’s local
ethics committee because data are collected in an anonymous
form. Prospective data collection for AHOD commenced in
1999, with retrospective data provided where available. Data for
AHOD are collected from 27 clinical sites throughout Australia,
including hospitals, sexual health clinics, and general medical
practices.Written, informed consent is obtained from all patients
recruited to AHOD at the time of enrolment. Ethical approval for
both TAHOD and AHOD was obtained from the University of
New SouthWales, Sydney, Australia, and all other relevant insti-
tutional reviewboards. All TAHODandAHODstudy procedures
were developed in accordance with the revised 1975 Helsinki
Declaration Data for both cohorts are transferred electronically
to the National Centre in HIV Epidemiology and Clinical
Research (NCHECR) every March and September and include
the same set of core variables. All data are subject to standardized
quality control procedures.
For this analysis, we included patients recruited to the
TAHOD, and the AHOD, whoever started cART (defined as
3 or more antiretroviral drugs in combination). Ethnicity is
consistently reported in TAHOD and more than 95% are
known to be Asian (29% Chinese, 25% Thai, and 14% Indian)
and <1% are known to beWhite/Caucasian. In AHOD, ethnicity
is inconsistently available (known in about 48% of patients,
n ¼ 1103). Where available, greater than 90% are known to be
Caucasians in AHOD. HIV seroconversion surveys in Australia
consistently report White/Caucasian ethnicity at greater than
80%.13,14 We therefore assume that AHOD largely represents
a Caucasian population. We defined study entry date as later of
cohort entry date or cART start date. Patients were also required
to have at least one follow-up visit after the study entry date.
Study Endpoints
The primary endpoint of this study was a combined endpoint of
progression to newly diagnosed AIDS-defining illness or death
from any cause. The definition of AIDS diagnosis was adapted
using a modified version of the revised 1993 CDC case defini-
tion for AIDS,15 excluding CD4 counts less than 200/mm3.
The secondary endpoint was all-causemortality.We considered
patients with no contact for at least 12 months prior to March 31,
2009 (the censorship date), whowere not known tomeet the study
endpoints, to be lost to follow-up (LTFU). Follow-up data were
censored at the first of: lost to follow-up or the censorship date.
Statistical Analysis
We compared the baseline data between the TAHOD and
AHOD cohorts using Mann-Whitney Rank sum test or Student
t-test for continuous variables and chi-square test for categori-
cal variables. For the follow-up analysis, we used CD4 count/
mm3 and HIV RNA load copies/mL as time-updated variables,
lagged by 3 months (ie, not updated until 3 months even if a
more recent value was measured) since a clinical event may
influence the latest (most recent) values. We then calculated
incidence of AIDS or death and all-cause mortality in each
cohort, stratified by latest CD4 counts (lagged by 3 months and
categorized as <50, 50-100, 100-200, 200-350, 350-500, and
>500 cells/mm3). We used Cox regression models with time-
updated variables to model the relationship between latest
CD4 count lagged by 3 months (categorized as above) and each
of the endpoints. To examine for heterogeneity in this relation-
ship between the 2 cohorts, we included an interaction term, as
a product of cohort (TAHOD/AHOD) and latest CD4 counts
lagged by 3 months. Models were a priori adjusted for fixed
covariates, including cohort (TAHOD/AHOD), gender, hepati-
tis B and C coinfection (defined as HBV surface antigen and
HCV antibody positive, respectively), HIV exposure category
(homosexual contact+ Intravenous drug user [IDU], IDU +
heterosexual, heterosexual, and other), and prior AIDS; and
time-updated covariates including HIV RNA category lagged
by 3 months (categorized as <500, 500-10 000, and >10 000
copies/mL), age, on or off cART, calendar year (categorized
as earlier than 2000, 2000-02, 2002-04, 2004-06, 2006-08, and
later than 2008) and new AIDS (for mortality endpoint only).
For all time-updated variables, missing data were imputed by
carrying forward (but not backward) the last observation, till
the last follow-up date. The proportional hazard assumption
for cohort variable and each of the endpoints, assessed by
Schoenfeld residuals test, was not found to be violated.
We conducted the following sensitivity analysis: (1) Since
the rate of LTFU in those with CD4 counts <50 cells/mm3 was
found to be different between TAHOD and AHOD, we used the
method suggested by Egger et al,16 to assess the possible
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impact of differential pattern in LTFU. First, we calculated the
mortality rate in those who remained in follow-up with latest
CD4 counts <50 cells/mm3 in TAHOD. We assumed the mor-
tality rate of 40% (95% CI 33%-48%) in LTFU patients from
TAHOD with latest CD4 counts <50 cells/mm3.17 We then
calculated the overall mortality in this group weighted by the
proportion LTFU and not LTFU, which is presented in
Figure 2b; (2) Since AHOD tend to have laboratory measure-
ments more frequently, we adjusted the frequency of CD4
count and HIV RNA measurements in AHOD to mirror
TAHOD, by excluding the every second measurement in
AHOD; (3) censoring tuberculosis-related AIDS diagnosis or
deaths with tuberculosis as an underlying cause; (iv) using latest
(time-updated) CD4 counts andHIVRNA levels, without lagging
(ie, using the most recent measurements); and (v) including only
those from AHOD with known Caucasian ethnicity.
Data were analyzed using Stata version 10 (Stata Corporation,
College Station, Texas).
Figure 1. Incidence rates per 100 person years of (a) AIDS or death and (b) all-cause mortality by latest CD4 count per mm3 (lagged by 3 months) in
TREATAsiaHIVObservationalDatabase (TAHOD)andAustralianHIVObservationalDatabase (AHOD).Errorbars represent95%confidence intervals.
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Results
Patient Characteristics at Study Entry
A total of 5668 patients (3356 from TAHOD and 2312 from
AHOD)were included in the analysis, contributing 23 144 person
years of follow-up (PYFU). The patient characteristics at study
entry in TAHOD and AHOD are shown in Table 1. Participants
from TAHOD were more likely than those from AHOD,
respectively, to be: younger (mean age in years: 38vs. 43), female
(28.6% vs. 5.8%), report as heterosexually acquired infection
(69.3% vs. 9.2%), have hepatitis B coinfection (7.1% vs. 5.1%),
prior AIDS (46.8% vs. 20.3%), detectable HIV RNA load (52%
vs. 40.6%), lower median CD4 count (259 cells/mm3 vs. 432
cells/mm3), less time spent on cART, and to be on nonnucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen (75.6% vs
48.7%). Also, a higher proportion of TAHOD participants had
missing hepatitis B and C coinfection status (Table 1).
CD4 Count and Risk of AIDS or Death in
TAHOD and AHOD
There were a total of 382 AIDS or death events in TAHOD
(incidence rate per 100 PYFU: 4.06, 95% CI: 3.68-4.50) and
305 events in AHOD (incidence rate per 100 PYFU: 2.39,
95% CI: 2.13-2.67). Incidence rates of AIDS or death, stratified
by latest CD4 count (lagged by 3 months), in TAHOD and
AHOD are plotted in Figure 1a. At any given CD4 count
category, the rates of AIDS or death were found to be similar
between TAHOD and AHOD, except in lowest category
(<50 cells/mm3), where TAHOD tended to have lower rate
(Figure 1a).
In the multivariable model (Table 2), the risk of AIDS or
death increased with decreasing CD4 counts. There was no sta-
tistically significant interaction by cohort (TAHOD/AHOD)
and time-updated CD4 count category (lagged by 3 months)
in predicting AIDS or death (P ¼ .256 for the interaction term)
(Table 2). Among the other covariates included in the model,
age, HIV RNA, hepatitis B and C coinfection, and prior AIDS
were associated with higher risk and being on cART was
associated with lower risk of AIDS or death (data not shown).
CD4 Count and Risk of All-Cause
Mortality in TAHOD and AHOD
There were a total of 135 deaths in TAHOD (incidence rate per
100 PYFU: 1.36, 95% CI: 1.15-1.61) and 206 deaths in AHOD
(incidence rate per 100 PYFU: 1.56, 95% CI: 1.36-1.78). Rates
of death in TAHOD and AHOD, stratified by latest CD4 count
(lagged by 3 months), are plotted in Figure 1b. Similar to the
AIDS or death endpoint, the mortality rates were found to be
similar between TAHOD and AHOD at any given CD4 count
category, except in lowest category (<50 cells/mm3), where
TAHOD tended to have lower rate (incidence-rate: 12, 95%
CI: 9.2-17) as compared to AHOD (incidence-rate: 21.5, 95%
CI: 16-28.7), per 100 PYFU (Figure 1b).
In the multivariable model (Table 3), the risk of death
increased with decreasing CD4 counts. Overall risk of death
in the adjusted model (excluding the interaction term) was sim-
ilar between TAHOD and AHOD (HR for TAHOD vs AHOD:
0.84, 95% CI: 0.53-1.33). Similar to the AIDS or death end-
point, there was no statistically significant interaction by cohort
(TAHOD/AHOD) and time-updated CD4 count category
(lagged by 3 months) in predicting death (P ¼ .254 for the
interaction term; Table 2). The other predictors associated with
increased risk of death included age, HIV RNA, hepatitis B
and C coinfection, and prior AIDS (data not shown).
Table 1. Patient Characteristics at Study Entry
Characteristics
TAHOD,
n ¼ 3356 n (%)
AHOD,
n ¼ 2312 n (%) Pa
Age (years)
Mean 38 43 <.001
<30 565 (16.8) 154(6.6) <.001
30-40 1564 (46.6) 852 (36.8)
40-50 838 (25.0) 800 (34.6)
50-60 274 (8.1) 376 (16.3)
>60 115 (3.4) 130 (5.6)
Sex
Male 2393(71.3) 2171(93.9) <.001
Female 960 (28.6) 134 (5.8)
Transgender 3 (0.09) 7 (0.3)
HIV exposure category
Homosexual contact
+ IDU
652 (19.4) 1891 (81.8) <.001
IDU + heterosexual 123 (3.7) 56 (2.4)
Heterosexual 2326 (69.3) 212 (9.2)
Other 248 (7.4) 127 (5.5)
Missing 7 (0.2) 26 (1.1)
Hepatitis B coinfection
Negative 2024 (60.3) 1823 (78.8) <.001
Positive 239 (7.1) 119 (5.1)
Missing/never tested 1093 (32.5) 370 (16.0)
Hepatitis C coinfection
Negative 1817 (54.1) 1782 (77.0) <.001
Positive 191 (5.7) 273 (11.8)
Missing/never tested 1348 (40.2) 257 (11.1)
HIV RNA <500 copies/
mL
1615 (48.1) 1373(59.4) <.001
Prior AIDS at study
entry
1825 (46.8) 511 (20.3) <.001
Median CD4 count per
mm3 (IQR)
259 (144-399) 432 (262-640) <.001b
ART Class at baseline
NRTI 3192 (95.1) 2030 (87.8) <.005
NNRTI 2549 (75.6) 1126 (48.7)
PI 760 (22.6) 971 (42.0)
Other 9 (0.3) 20 (0.9)
Median duration of
cART in months (IQR)
13 (2.3-30.3) 32 (10.3-45.6) <.001b
a Comparison by t-test for continuous variables and the w2 test for noncontin-
uous variables.
b Comparison by Wilcoxon rank-sum test.
Abbreviations: TAHOD, TREAT Asia HIV Observational Database; AHOD,
Australian HIV Observational Database; IDU, Intravenous drug user; IQR,
inter-quartile range; CD4 count refers to CD4 T-cell count; ART, antiretroviral
therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI,
non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Achhra et al 163
 at YONSEI UNIV LIBRARY on November 19, 2013jia.sagepub.comDownloaded from 
Loss to Follow-Up in TAHOD and AHOD
and Its Impact on Mortality Estimates
The risk of both the endpoints, AIDS or death and all-cause
mortality, tended to be lower in TAHOD in the lowest CD4
category (<50 cells/mm3). Since this was unexpected,
we examined for possible differential patterns in loss to fol-
low-up.
A total of 727 patients from TAHOD and 618 patients from
AHOD were lost to follow-up, at the rate of 7.33 (95%
CI: 6.81-7.88) and 4.67 (95% CI: 4.31-5.05), per 100 PYFU,
respectively. To investigate the possibility that the patients
with severe disease were more likely to be lost to follow-up
in TAHOD, we compared the rates of loss to follow-up, strati-
fied by latest CD4 count (lagged by 3 months), between
TAHOD and AHOD, as illustrated in Figure 2a. The rates of
loss to follow-up tended to bemarkedly higher inTAHODas com-
pared to AHOD in the lowest CD4 count category (Figure 2a).
The loss to follow-up rate for TAHODandAHODpatients with
last knownCD4 count (lagged by 3months) <50 cells/mm3was
13.90 (95% CI: 10.03-19.28) and 3.03 (95% CI: 1.44-6.36),
per 100 PYFU, respectively.
Table 2. Adjusted Analyses for AIDS or Death
Parameters
Adjusted Analysisa
HR 95% CI P
Latest CD4 count per mm3
(lagged by 3-months)
>500 Reference
350-500 1.43 1.00-2.05 .05
200-350 2.02 1.42-2.86 <.001
100-200 3.07 2.03-4.66 <.001
50-100 5.35 3.19-8.97 <.001
<50 15.44 10.34-23.08 <.001
Cohort AHOD Reference
TAHOD 1.53 0.92-2.55 0.100
Interaction termb 0.256b
Abbreviations: HR, Hazard ratio; TAHOD, TREAT Asia HIV Observational Database; AHOD, Australian HIV Observational Database; CD4 count refers to CD4
T-cell count.
a Models were a priori adjusted for fixed covariates, including cohort (TAHOD/AHOD), gender, hepatitis B and C coinfection, HIV exposure category, and prior
AIDS; and time-updated covariates including HIV RNA category lagged by 3 months (categorized as <500, 500-10 000, and >10 000 copies/mL), age, on or off
cART, calendar year (categorized as earlier than 2000, 2000-2002, 2002-2004, 2004-2006, 2006-2008, and later than 2008) and new AIDS (for mortality endpoint
only).
b P value is for the interaction term (product of cohort [TAHOD/AHOD] and categorized CD4 count lagged by 3 months), obtained in the adjusted model
predicting respective endpoint. Excluding the interaction term from the multivariable model changes the HR for cohort (TAHOD vs. AHOD) to 1.43 (95%
CI: 1.02-2.00) for AIDS or death and 0.84 (95% CI: 0.53-1.33) for all-cause mortality.
Table 3. Adjusted Analyses for All-Cause Mortality
Parameters
Adjusted Analysisa
HR 95% CI P
Latest CD4 count per mm3 (lagged by 3-months) >500 Reference
350-500 1.36 0.83-2.19 .212
200-350 2.44 1.58- 3.77 <.001
100-200 3.81 2.30-6.31 <.001
50-100 4.11 1.94-8.69 <.001
<50 21.56 13.12-35.45 <.001
Cohort AHOD Reference
TAHOD 0.48 0.18-1.32 .157
Interaction termb .254b
Abbreviations: HR, Hazard ratio; TAHOD, TREAT Asia HIV Observational Database; AHOD, Australian HIV Observational Database; CD4 count refers to CD4
T-cell count.
a Models were a priori adjusted for fixed covariates, including cohort (TAHOD/AHOD), gender, hepatitis B and C coinfection, HIV exposure category, and prior
AIDS; and time-updated covariates including HIV RNA category lagged by 3 months (categorized as <500, 500-10,000, and >10,000 copies/mL), age, on or off
cART, calendar year (categorized as earlier than 2000, 2000-02, 2002-04, 2004-06, 2006-08, and later than 2008) and new AIDS (for mortality endpoint only).
b P value is for the interaction term (product of cohort (TAHOD/AHOD) and categorized CD4 count lagged by 3-months), obtained in the adjusted model
predicting respective endpoint. Excluding the interaction term from the multivariable model changes the HR for cohort (TAHOD vs. AHOD) to 1.43 (95%
CI: 1.02-2.00) for AIDS or death and 0.84 (95% CI: 0.53-1.33) for all-cause mortality.
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The mortality in those who remained in the follow-up in
TAHOD, with latest CD4 count <50 cells/mm3, was found to
be 16 per 100 PYFU (or 16%). After adjusting for assumed
mortality in the LTFU group, the overall mortality rate in
TAHOD with latest CD4 counts <50 cells/mm3 was estimated
to range from 18% to 20%, which is similar to 21.5% reported
for AHOD in the same CD4 count category (Figure 2b).
Other Sensitivity Analyses
Results from all of the other sensitivity analyses were broadly
similar (Figure 3). Censoring tuberculosis-related AIDS
diagnosis or deaths with tuberculosis as an underlying
cause (n ¼ 180 in TAHOD and 4 in AHOD) slightly increased
the difference in absolute risk of AIDS or death at lowest CD4
Figure 2. a, Rate of loss to follow-up, per 100 person years, by last known CD4 count per mm3 (lagged by 3 months), in TREAT Asia HIV
Observational Database (TAHOD) and Australian HIV Observational Database (AHOD). Error bars represent 95% confidence intervals. b,
Overall estimated all-cause mortality rate in TAHOD (with latest CD4 count <50 cells/mm3), after accounting for assumed mortality rates
in those who were lost to follow-up (LTFU), and the comparison with observed rate in AHOD. The higher the assumed mortality in LTFU
patients, the similar are the mortality rates between TAHOD and AHOD. Error bars represent 95% confidence intervals.
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Figure 3. Incidence rate of AIDS or death (left vertical panel) and all-cause mortality (right vertical panel), by latest CD4 count (cells/mm3), in
TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD). *P value is for the interaction term
(product of cohort [TAHOD/AHOD] and categorized CD4 count lagged by 3 months), obtained in the multivariate models predicting respec-
tive endpoint, adjusted for same covariates as listed in Tables 2 and 3. The data are when (a) every second time-dependent CD4 count excluded
in AHOD; (b) censoring tuberculosis-related AIDS diagnosis or deaths with tuberculosis as an underlying cause; and (c) using latest (time-
updated) CD4 counts and HIV RNA levels, without lagging (ie, using the recent most measurements). The latest CD4 counts were lagged
by 3 months in (a) and (b). Error bars represent 95% confidence intervals.
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count category (lagged by 3 months) between TAHOD and
AHOD (Figure 3); since tuberculosis was more common in
TAHOD in lowest CD4 category. Also, the hazard of AIDS
or death in TAHOD, relative to AHOD, became closer to 1
(HR: 1.26, 95%CI: 0.88-1.80), suggesting that the overall
higher rate of AIDS events in TAHOD were largely explained
by tuberculosis. More importantly, the interaction term in the
multivariate model remained nonsignificant in all of the sensi-
tivity analyses (Figure 3) and also if only those from AHOD
with known Caucasian ethnicity were included (P ¼ .25 for
AIDS or death).
Discussion
In this study, we examined the clinical significance of
previously reported interethnic variations in the CD4 count
between Asian and Caucasian populations. We found that the
prognostic significance of the CD4 count, in terms of AIDS
or death and all-cause mortality, was not found to vary between
Asian and Caucasian HIV-infected individuals. In other words,
a given low CD4 count level engenders a similar magnitude
of risk of AIDS or death and all-cause mortality in the 2
populations.
The TAHOD patients tended to have lower rates of AIDS or
death and all-cause mortality at very low CD4 counts
(<50 cells/mm3), possibly suggesting that Asian populations
may have some survival advantage at low CD4 counts.
However, we believe these findings are a result of differential
rate of loss to follow-up between cohorts, as patients with
TAHOD having lower CD4 counts were more likely to be lost
to follow-up than patients with AHOD. Higher rate of loss to
follow-up in those with severer disease has previously been
reported from other cohorts in low-income countries.17-19 Our
sensitivity analyses showed if we adjusted for this potential
excess of events in those who were LTFU, then the rates in
TAHOD tend to be more similar to that in AHOD (Figure 2b).
Also, in the multivariate model, the cohort type was not found
to be an effect modifier of CD4 counts, suggesting that other
factors in the model may have explained this difference. Lastly,
even if there is a true difference in risk of endpoints between
TAHOD and AHOD, it is unlikely to be clinically significant,
as cART initiation or modification would be indicated at these
low CD4 counts, irrespective of the magnitude of the risk.
A study on an Ethiopian cohort, an ethnicity known to have
lower CD4 counts compared with Caucasians, suggested that
the lower preseroconversion CD4 counts (ie, lower CD4 counts
in healthy state) do not imply shorter survival times in Ethio-
pians, presumably because of slower decline in CD4 counts.20
Further, the previously reported differences in CD4 counts
between HIV-infected Asians and Caucasians were only signif-
icant at higher CD4 percentages, where clinical events are less
likely to occur.9 In addition, mortality rates in Asian (and
African populations who are known to have lower CD4 counts
in HIV-negative individuals) are reported to approach those in
Caucasian populations within few months after cART initia-
tion.19,21,22 Our findings support these observations, which
collectively suggest that the ethnicity may not be an important
factor and the CD4 thresholds defined for Caucasian
HIV-infected populations should be broadly appropriate for
Asian HIV-infected populations. Although 2 studies from
Hong Kong suggested that lower CD4 thresholds for cART
initiation may be appropriate among Asian populations, these
studies were limited by small sample size and a smaller number
of clinical endpoints (<30 in both studies).23,24 Our data do not
support the need for different thresholds for the 2 populations.
This comparison between Asian and Caucasian populations
was performed on treated HIV-infected individuals and may
have limited generalizability to untreated HIV-infected
individuals. Further, our cohort (especially TAHOD) may rep-
resent a selected group who has survived the initial few months
on cART, as mortality is known to be higher in patients from
low-income countries in first 3 to 4 months of treatment, as
compared to those from high-income countries.19,22 However,
this increased mortality in earlier months of cART is due
mainly to comorbidities, cART toxicities, lack of access to
health care, and the immune reconstitution inflammatory syn-
drome (IRIS).19,22,25-28 Consequently, our analysis is protected
from confounding by these factors and is likely to represent the
true risk of endpoints at various CD4 strata. Further, we also
performed sensitivity analysis by censoring tuberculosis-
related events, as tuberculosis is known to be more prevalent
in Asian countries29 and is a common form of IRIS.25,28
The results from sensitivity analyses were largely similar.
There were a few other limitations to our analysis. Firstly,
the 2 populations are highly heterogeneous, including different
treatment patterns, and our multivariable models may not have
accounted for all factors. Ideally, such a comparison should be
performed between Caucasians and Asians who are raised in
Western countries. Also, ascertaining of ethnicity is incomplete
in AHOD and it is likely that there may be some patients of
Asian ethnicity in the AHOD, possibly resulting in misclassifi-
cation. However, where ethnicity is recorded in AHOD, more
than 90% are Caucasians and also, sensitivity analysis with
only those AHOD patients with known Caucasian ethnicity
yielded similar results. Further, we did not account for different
subtypes of HIV-1 that may be prevalent in the 2 cohorts.30
However, there is little evidence of subtype differences in dis-
ease progression or response to cART.31,32 Second, we did not
divide Asian ethnicity into its various subtypes (eg, Indians,
Thai, Chinese, etc), to avoid loss of power. However, this is
unlikely to influence our results as CD4 counts are known to
be similar among various Asian populations.5,6,33 Third, hepa-
titis coinfection status was missing from a significant propor-
tion of TAHOD participants, which is especially important as
hepatitis C coinfection is known to be responsible for signifi-
cant mortality in HIV/HCV coinfected population.34,35
The study has several strengths. Firstly, this is a prospective
study including a large group of patients on a variety of antire-
troviral agents followed for a prolonged period of time.
Also, we analyzed the broad endpoints of AIDS or death and
all-cause mortality, which include non-AIDS deaths; as recent
data suggest that latest CD4 counts are associated with risk of
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non-AIDS events.36-38 Lastly, use of data from 2 observational
cohort studies founded on the same methodology is a major
strength of our study, reducing the likelihood of confounding
due to methodological differences.
In summary, the risk ofAIDSor death and all-causemortality
at any given CD4 count strata was not found to vary between
Asian and Caucasian populations. These findings suggest, albeit
indirectly, that the CD4 thresholds defined on Caucasian popu-
lations are broadly appropriate in Asian populations. Further,
these findings provide an appropriate evidence base on Asian
populations for the CD4 count thresholds recommended for
initiating cART and prophylaxis for opportunistic infections.
Acknowledgments
This study has been presented at the 14th International Workshop of
HIV Observational Databases (IWHOD), Barcelona, Spain, 2010
(abstract no.:92) and at 22nd Annual Conference for the Australasian
Society for HIV Medicine, Sydney, 2010 (abstract no. 356).
The writing committee would like to acknowledge several thousands
of patients, the TAHOD Steering Committee [The TREAT Asia HIV
Observational Database: CV Mean, V Saphonn* and K Vohith,
National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh,
Cambodia; FJ Zhang*, HX Zhao and N Han, Beijing Ditan Hospital,
Beijing, China; PCK Li* and MP Lee, Queen Elizabeth Hospital,
Hong Kong, China; N Kumarasamy*, S Saghayam and C Ezhilarasi,
YRG Centre for AIDS Research and Education, Chennai, India;
S Pujari*z, K Joshi, and A Makane, Institute of Infectious Diseases,
Pune, India; TP Merati*, DN Wirawan and F Yuliana, Faculty of
Medicine Udayana University & Sanglah Hospital, Bali, Indonesia;
E Yunihastuti* and O Ramadian, Working Group on AIDS Faculty
of Medicine, University of Indonesia/ Ciptomangunkusumo Hospital,
Jakarta, Indonesia; S Oka*, J Tanuma and M Honda, National Center
for Global Health and Medicine, Tokyo, Japan; JY Choi*, SH Han,
and JM Kim, Division of Infectious Diseases, Dept. of Internal
Medicine, Yonsei University College of Medicine, Seoul,
South Korea; C KC Lee*, B HL Sim and R David, Hospital Sungai
Buloh, Kuala Lumpur, Malaysia; A Kamarulzaman* and A Kajindran,
University of Malaya Medical Centre, Kuala Lumpur, Malaysia;
G Tau, Port Moresby General Hospital, Port Moresby, Papua New
Guinea**; R Ditangco*, E Uy and R Bantique, Research Institute for
Tropical Medicine, Manila, Philippines; YMA Chen*, WWWong and
LH Kuo, Taipei Veterans General Hospital and AIDS Prevention and
Research Centre, National Yang-Ming University, Taipei, Taiwan;
PL Lim*, A Chua and E Foo, Tan Tock Seng Hospital, Singapore;
P Phanuphak*, Kiat Ruxrungtham and M Khongphattanayothin,
HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok,
Thailand; S Sungkanuparph*, S Kiertiburanakul and B Piyavong,
Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand; T Sirisanthana*y, R Chaiwarith and W Kotarathi-
titum, Research Institute for Health Sciences, Chiang Mai, Thailand;
AH Sohn*, L Messerschmidt* and B Petersen, TREAT Asia,
amfAR—The Foundation for AIDS Research, Bangkok, Thailand;
J Chuah*, Gold Coast Sexual Health Clinic, Miami, Queensland,
Australia; DA Cooper, MG Law*, J Zhou* and A Jiamsakul, National
Centre in HIV Epidemiology and Clinical Research, The University
of New South Wales, Sydney, Australia. *TAHOD Steering
Committee member; **Inactive site; y Steering Committee Chair;
z co-Chair. TAHOD reviewers: PCK Li, MP Lee, S Vanar, S Faridah,
A Kamarulzaman, JY Choi,B Vannary, R Ditangco, K Tsukada,
SH ?A3B2 twb=0.39w?> Han, FJ Zhang,YMA Chen, N Kumarasay,
A Dravid, OT Ng, C Duncombe, S Sungkanuparph, T Sirisanthana.
Independent reviewers: F Drummond, M Boyd] and the AHOD
Steering Committee [The Australian HIV Observational Database:
D Ellis, General Medical Practice, Coffs Harbour, NSW; J Chuah*,
M Ngieng, B Dickson, Gold Coast Sexual Health Clinic, Miami,
QLD;M Bloch, T Franic, S Agrawal, N Cunningham Holdsworth
House General Practice, Darlinghurst, NSW; R Moore, S Edwards,
P Locke, Northside Clinic, North Fitzroy, VIC; D Nolan, C Forsdyke,
J Skett, Department of Clinical Immunology, Royal Perth Hospital,
Perth, WA; NJ Roth*y, J Nicolson, Prahran Market Clinic, South
Yarra, VIC; D Allen, P Maudlin Holden Street Clinic, Gosford, NSW;
D Smith, C Mincham, C Gray Lismore Sexual Health & AIDS
Services, Lismore, NSW; D Baker*, R Vale, East Sydney Doctors,
Darlinghurst, NSW; D Russell, S Downing, Cairns Sexual Health
Service, Cairns, QLD; D Templeton, C O’Connor, Royal Prince
Alfred Hospital Sexual Health, Camperdown, NSW; D Sowden,
K McGill, Clinic 87, Sunshine Coast & Cooloola HIV Sexual Health
Service, Nambour, QLD; D Orth; D Youds, Gladstone Road Medical
Centre, Highgate Hill, QLD; E Jackson, Blue Mountains Sexual
Health and HIV Clinic, Katoomba, NSW; T Read, J Silvers,
Melbourne Sexual Health Centre, Melbourne, VIC; A Kulatunga,
P Knibbs, Communicable Disease Centre, Royal Darwin Hospital,
Darwin, NT; J Hoy, K Watson*, M Bryant, S Price, The Alfred
Hospital, Melbourne, VIC; M Gotowski, S Taylor, L Stuart-Hill,
Tamworth Sexual Health Service, Tamworth, NSW; D Cooper,
A Carr, K Hesse, R Norris St Vincent’s Hospital, Darlinghurst, NSW;
R Finlayson, I Prone, Taylor Square Private Clinic, Darlinghurst,
NSW; MT Liang, Nepean Sexual Health and HIV Clinic, Penrith,
NSW; M Kelly, A Gibson, H Magon, AIDS Medical Unit, Brisbane,
QLD; K Brown, N Skobalj, Illawarra Sexual Health Clinic,
Warrawong, NSW; L Wray, H Lu, Sydney Sexual Health Centre,
Sydney, NSW; W Donohue,The Care and Prevention Programme,
Adelaide University, Adelaide, SA; I Woolley, M Giles, T Korman,
Monash Medical Centre, Clayton, VIC; Dubbo Sexual Health Centre,
Dubbo, NSW; P Canavan*, National Association of People Living
with HIV/AIDS; C Lawrence*, National Aboriginal Community
Controlled Health Organisation; B Mulhall*, School of Public Health,
University of Sydney, Sydney, NSW; M Law*, K Petoumenos*,
S Marashi Pour*, Courtney Bendall*, National Centre in HIV
Epidemiology and Clinical Research, University of NSW, Sydney;
NSW.*Steering Committee member 2010, y Current Steering
Committee chair.Cause of Death (CoDE) reviewers AHOD reviewers:
D Sowden, DTempleton, ACarr, J Hoy, LWray, J Chuah, KMorwood,
T Read, N Roth, I Woolley, M Kelly, J Broom.]
Declaration of Conflicting Interests
The author(s) declared no conflicts of interest with respect to the
authorship and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article: The TREAT Asia HIV
Observational Database and the Australian HIV Observational Data-
base are part of the Asia Pacific HIV Observational Database and are
initiatives of TREAT Asia, a program of amfAR, The Foundation for
AIDS Research, with support from the following institutes of the
U.S. National Institutes of Health (NIH): National Institute of Allergy
and Infectious Diseases (NIAID), National Institute of Child Health
and Human Development (NICHD), the Office of the Director (OD),
168 Journal of the International Association of Physicians in AIDS Care 10(3)
 at YONSEI UNIV LIBRARY on November 19, 2013jia.sagepub.comDownloaded from 
and theNational Cancer Institute (NCI), as part of the International Epi-
demiologic Databases to Evaluate AIDS (IeDEA) (grant no.
U01AI069907). Additional support is provided by the DutchMinistry
of Foreign Affairs through a partnership with Stichting Aids Fonds.
The National Centre in HIV Epidemiology and Clinical Research is
funded by the Australian Government Department of Health and
Ageing, and is affiliated with the Faculty ofMedicine, The University
of New South Wales. The content of this publication is solely the
responsibility of the authors and does not necessarily represent the
official views of any of the institutions mentioned above.
References
1. World Health Organisation. HIV /AIDS in the South-East Asia
Region. 2009. http://www.searo.who.int/LinkFiles/Publications_
HIV_AIDS_Report2009.pdf. Accessed June 15, 2010.
2. Hammer SM, Eron JJ, Jr, Reiss P, et al. Antiretroviral treatment of
adult HIV infection: 2008 recommendations of the International
AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
3. Kadhiravan T, Sharma SK. Mortality of HIV-infected patients in
low-income countries. Lancet. 2006;368(9554):2207-2207.
4. World Health Organisation. Rapid advice: Antiretroviral therapy
for HIV infectionin adults and adolescents. 2009. http://
www.who.int/hiv/pub/arv/rapid_advice_art.pdf. Accessed June
15, 2010.
5. Chng WJ, Tan GB, Kuperan P. Establishment of adult peripheral
blood lymphocyte subset reference range for an Asian population
by single-platform flow cytometry: influence of age, sex, and race
and comparison with other published studies. Clin Diagn Lab
Immunol. 2004;11(1):168-173.
6. Das BR, Bhanushali AA, Khadapkar R, Jeswani KD, Bhavsar M,
Dasgupta A. Reference ranges for lymphocyte subsets in adults
from western India: influence of sex, age and method of enumera-
tion. Indian J Med Sci. 2008;62(10):397-406.
7. Jiang W, Kang L, Lu HZ, et al. Normal values for CD4 and
CD8 lymphocyte subsets in healthy Chinese adults from Shanghai.
Clin Diagn Lab Immunol. 2004;11(4):811-813.
8. Webster HK, Pattanapanyasat K, Phanupak P, et al. Lymphocyte
immunophenotype reference ranges in healthy Thai adults: impli-
cations for management of HIV/AIDS in Thailand. Southeast
Asian J Trop Med Public Health. 1996;27(3):418-429.
9. Achhra AC, Zhou J, Dabis F, et al. Difference in absolute CD4þ
count according to CD4 percentage between Asian and Caucasian
HIV-Infected patients. J AIDS Clinic Res. 2010;1:101.
10. Egger S, Petoumenos K, Kamarulzaman A, et al. Long-term
patterns in CD4 response are determined by an interaction
between baseline CD4 cell count, viral load, and time: The Asia
Pacific HIV Observational Database (APHOD). J Acquir Immune
Defic Syndr. 2009;50(5):513-520.
11. Australian HIV Observational Database. Rates of combination
antiretroviral treatment change in Australia, 1997-2000.
HIV Med. 2002;3(1):28-36.
12. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV
Observational Database: baseline and retrospective data. J Acquir
Immune Defic Syndr. 2005;38(2):174-179.
13. Prestage G, Bradley J, Down I, et al. HIV Seroconversion Study.
Newly diagnosed men in Australia. 2009. http://www.nchecr.unsw.
edu.au/nchecrweb.nsf/resources/QldSurv/$file/SeroconReportOct09.
pdf. Accessed August 9, 2010.
14. Volk JE, PrestageG, Jin F, et al. Risk factors forHIV seroconversion
in homosexual men in Australia. Sexual Health. 2006;3(1):45-51.
15. 1993 revised classification system for HIV infection and
expanded surveillance case definition for AIDS among adoles-
cents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
16. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss
to follow-up: a nomogram applied to antiretroviral treatment pro-
grammes in sub-saharan Africa. PLoS Med. 2011;8(1):e1000390.
17. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of
patients lost to follow-up in antiretroviral treatment programmes
in resource-limited settings: systematic review and meta-analysis.
PLoS One. 2009;4(6):e5790.
18. Anglaret XMDP, Toure SMDM, Gourvellec GM, et al. Impact of
Vital Status Investigation Procedures on Estimates of Survival in
Cohorts of HIV-Infected Patients From Sub-Saharan Africa.
[Report]. JAIDS. 2004;35(3):320-323.
19. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-
infected patients in the first year of antiretroviral therapy: compar-
ison between low-income and high-income countries. Lancet.
2006;367(9513):817-824.
20. MekonnenY,GeskusRB,Hendriks JC, et al. LowCD4Tcell counts
before HIV-1 seroconversion do not affect disease progression in
Ethiopian factory workers. J Infect Dis. 2005;192(5):739-748.
21. Brinkhof MWG, Egger M, Schechter M, Dabis F. Mortality of
HIV-infected patients in low-income countries–Authors’
response. Lancet. 2006;368(9554):2207-2208.
22. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China
National Free Antiretroviral Treatment Program. Ann Intern Med.
2009;151(4):241-251, W-252.
23. Ho C, Lee S, Wong K, Cheng L, Lam M. Setting a minimum
threshold CD4 count for initiation of highly active antiretroviral
therapy in HIV-infected patients. HIV Med. 2007;8(3):181-185.
24. Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SS.
Establishing CD4 thresholds for highly active antiretroviral ther-
apy initiation in a cohort of HIV-infected adult Chinese in Hong
Kong. AIDS Patient Care STDS. 2007;21(2):106-115.
25. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M.
Immune reconstitution inflammatory syndrome in patients
starting antiretroviral therapy for HIV infection: a systematic
review and meta-analysis. Lancet Infect Dis. 2010;10(4):251-261.
26. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia.
Lancet. 2004;364(9428):69-82.
27. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X.
Risk factors for active tuberculosis after antiretroviral treatment initia-
tion in Abidjan. Am J Respir Crit Care Med. 2005;172(1):123-127.
28. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al.
Incidence and risk factors of major opportunistic infections after
initiation of antiretroviral therapy among advanced HIV-infected
patients in a resource-limited setting. J Infect. 2007;55(5):464-469.
29. World Health Organization. TB in South-East Asia. 2009.
http://www.searo.who.int/EN/Section10/Section2097/Section2100_
10639.htm. Accessed April 19, 2010.
30. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J.
Estimated global distribution and regional spread of HIV-1
Achhra et al 169
 at YONSEI UNIV LIBRARY on November 19, 2013jia.sagepub.comDownloaded from 
genetic subtypes in the year 2000. J Acquir Immune Defic Syndr.
2002;29(2):184-190.
31. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar
rate of disease progression among individuals infected with
HIV-1 genetic subtypes A-D. AIDS. 1999;13(8):901-907.
32. Geretti AnnaM,HarrisonL,GreenH, et al. Effect ofHIV–1 subtype
on virologic and immunologic response to starting highly active
antiretroviral therapy. Clin Infect Dis. 2009;48(9):1296-1305.
33. Ramalingam S, Kannangai R, Zachariah A, Mathai D, Abraham C.
CD4 counts of normal and HIV-infected south Indian adults: do we
need a new staging system? Natl Med J India. 2001;14(6):5.
34. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to
end–stage liver disease in patients with human immunodeficiency
virus infection. Clin Infect Dis. 2001;32(3):492-497.
35. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C
virus on immune restoration in HIV-infected patients who start
highly active antiretroviral therapy: a meta-analysis. Clin Infect
Dis. 2005;41(5):713-720.
36. Inferior Clinical Outcome of the CD4þ Cell Count-Guided
Antiretroviral Treatment Interruption Strategy in the SMART
Study: Role of CD4þ Cell Counts and HIV RNA Levels during
Follow-up. J Infect Dis. 2008;197(8):1145-1155.
37. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the
risk of serious clinical endpoints in a well studied cohort of treated
HIV-infected patients. AIDS. 2010;24(12):1877-1886.
38. Baker JV, Peng G, Rapkin J, et al. CD4þ count and risk of
non-AIDS diseases following initial treatment for HIV infection.
AIDS. 2008;22(7):841-848.
170 Journal of the International Association of Physicians in AIDS Care 10(3)
 at YONSEI UNIV LIBRARY on November 19, 2013jia.sagepub.comDownloaded from 
